Patent №
US 10,072,289
Granted
2018-09-11
Filed 2015
Owner
SYNAPTAMINE, INC.
+4 more
Lab
—
AI components
1
ml
Assignment
Recorded
Dataset
AIPD
2023_r1 edition
Application
14796989
Methods and kits for assessing severity index for alcohol abuse, drug abuse, and other reward deficiency syndromes. It has been discovered that a multifaceted non-specific RDS behaviors should be considered as the true “reward” phenotype (endophenotype) instead of a single subset RDS behavior such as alcoholism. In an embodiment of the present invention, it has been discovered that there are at least eleven risk alleles associated with ten candidate genes. The methods and kits of the present invention satisfy the need to classify patients at genetic risk for drug/alcohol seeking behavior prior to or upon entry to residential and or non-residential chemical dependency and pain programs.
AI classification
Ownership
SYNAPTAMINE, INC.
assignment · 362330970
IGENE LLC
assignment · 402310171
GENEUS HEALTH LLC
assignment · 503830232
GENEUS HEALTH IP, LLC
assignment · 511540386
IVITALIZE IP HOLDINGS, INC.
assignment · 596950609
Assignors
BLUM, KENNETH
On an employer assignment, the assignors are typically the inventors.